Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study

Biological Psychiatry

Volumn 44, Issue 8, 1998, Pages 748-754

  Berardi, Domenico ^a   Amore, Mario ^a   Keck Jr , Paul E ^b   Troia, Mario ^a   Dell'Atti, Maddalena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Agitation; Catatonia; Confusion; Dose; Neuroleptic malignant syndrome; Risk factors

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CASE CONTROL STUDY; CATATONIA; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DISORIENTATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RESTLESSNESS; RISK FACTOR;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032532192     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00530-1     Document Type: Article

References (60)

1. Addonizio G., Susman V.L., Roth S.D. Neuroleptic malignant syndrome Review and analysis of 115 cases . Biol Psychiatry. 22:1987;1004-1020.
2. Adityanjee, Singh S., Singh G., Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry. 153:1988;107-111.
3. Aizenberg D., Shalev A., Munitz H. The aftercare of the patient with the neuroleptic malignant syndrome. J Clin Psychiatry. 146:1985;317-318.
4. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. 1980;American Psychiatric Press, Washington, DC.
5. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. 1987;American Psychiatric Press, Washington, DC.
6. Barnes T.R.E., Braude W.M. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry. 42:1985;874-878.
7. Braude W.M., Barnes T.R.E., Gore S.M. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric in-patient admissions. Br J Psychiatry. 143:1983;139-150.
8. Caroff S.N. The neuroleptic malignant syndrome. J Clin Psychiatry. 41:1980;79-83.
9. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome. Psychopharmacol Bull. 24:1988;25-29.
10. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome. Med Clin North Am. 77:1993;185-202.
11. Davis J.M. Dose equivalence of the antipsychotic drugs. J Psychiatr Res. 11:1974;65-69.
12. Fricchione G.L. Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry. 20:1985;304-313.
13. Gelenberg A.J. The catatonic syndrome. Lancet. i:1976;1339-1341.
14. Gelenberg A.J., Mandel M.R. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry. 34:1977;947-950.
15. Giordani L., Amore M., Montanari A., Berlinzani L., Gentili C. Pridinolum mesylate and neuroleptic malignant syndrome [letter]. Am J Psychiatry. 142:1985;389-390.
16. Giordani L., Amore M., Montanari A., Berlinzani L., Gentili C. Letter reply. Am J Psychiatry. 143:1986;120-121.
17. Glantz S.A. Primer of Biostatistics. 1987;McGraw-Hill, New York.
18. Goeke J.E., Hagan D.S., Goelzer S.L., Coursin D.B. Lethal catatonia complicated by the development of neuroleptic malignant syndrome in a middle age female. Crit Care Med. 19:1991;1445-1448.
19. Greedharry D., Bowen R. Lethal catatonia and neuroleptic malignant syndrome [letter]. Can J Psychiatry. 38:1993;236-237.
20. Greenberg L.B., Gujavarty K. The neuroleptic malignant syndrome Review and report of three cases . Compr Psychiatry. 26:1985;63-70.
21. Grunhaus L., Sancovici S., Rimon R. Neuroleptic malignant syndrome due to depot fluphenazine. J Clin Psychiatry. 40:1979;99-100.
22. Harsch H.H. Neuroleptic malignant syndrome Physiological and laboratory findings in a series of nine cases . J Clin Psychiatry. 48:1987;328-333.
23. Hermesh H., Aizenberg D., Weizman A., Lapidot M., Mayor C., Munitz H. Risk for definite neuroleptic malignant syndrome A prospective study in 223 consecutive in-patients . Br J Psychiatry. 161:1992;254-257.
24. Hietala J., Syvalahti E., Vuorio K., Rakkolainen W., Bergman J., Haaparanta M., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
25. Itoh H., Ohtsuka N., Ogita K., Yagi G., Miura S., Koga Y. Malignant neuroleptic syndrome - Its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn. 31:1977;565-576.
26. Kaufmann C.A., Wyatt R.J. Neuroleptic malignant syndrome. Meltzer H. Psychopharmacology, The Third Generation of Progress. 1987;1421-1430 Raven Press, New York.
27. Keck P.E. Jr, Pope H.G., Cohen B.M., McElroy S.L., Nierenberg A.A. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry. 46:1989;914-918.
28. Keck P.E. Jr, Caroff S.N., McElroy S.L. Neuroleptic malignant syndrome - End of a controversy? J Neuropsychiatry Clin Neurosci. 7:1995;135-144.
29. Kontaxakis V.P., Vaidakis N.M., Christodoulou G.N., Valergaki H.C. Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome. Neuropsychobiology. 23:1990;38-40.
30. Lazarus A., Mann S.C., Caroff S.N. The Neuroleptic Malignant Syndrome and Related Conditions. 1989;American Psychiatric Press, Washington, DC.
31. Levenson J.L. Neuroleptic malignant syndrome. Am J Psychiatry. 142:1985;1137-1145.
32. Lotstra F., Linkowski P., Mendlewicz J. General anesthesia after neuroleptic malignant syndrome. Biol Psychiatry. 18:1983;243-247.
33. Mann S.C., Caroff S.N., Bleier H.R., Welz W.K.R., Kling M.A., Hayashida M. Lethal catatonia. Am J Psychiatry. 143:1986;1374-1381.
34. Meltzer H.Y. Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacology. 29:1973;337-346.
35. Meterissian G.B. Risperidone-induced neuroleptic malignant syndrome A case report and review . Can J Psychiatry. 41:1996;52-54.
36. Morris H.H., McCormick W.F., Reinarz J.A. Neuroleptic malignant syndrome. Arch Neurol. 37:1980;462-463.
37. Naganuma H., Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand. 90:1994;424-426.
38. Norusis MJ (1994): SPSS Statistical Package. Chicago, IL: SPSS Inc.
39. Osman A.A., Khurasani M.H. Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis. Br J Psychiatry. 165:1994;548-550.
40. Pelonero A.L., Levennson J.L., Silverman J.J. Neuroleptic therapy following NMS. Psychosomatics. 26:1985;946-948.
41. Pope H.G., Keck P.E. Jr, McElroy S.L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 143:1986;1227-1233.
42. Rogers D. Motor Disorders in Psychiatry Towards a Neurological Psychiatry . 1992;Wiley, Chichester, UK.
43. Rogers J.D., Stoudemire G.A. Neuroleptic malignant syndrome in multiple sclerosis Possible masking effects of antispasmodics . Psychosomatics. 29:1988;221-223.
44. Rosebush P.I., Stewart T.D. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 146:1989;717-725.
45. Rosebush P.I., MacQueen G.M., Clarke J.T.R., Callahan J.W., Strasberg P.M., Mazurek M.F. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia Diagnostic and treatment issues . J Clin Psychiatry. 56:1995;347-353.
46. Sachdev P. Akathisia and Restless Legs. 1995;Cambridge University Press, Cambridge.
47. Shalev A., Munitz H. The neuroleptic malignant syndrome Agent and host interaction . Acta Psychiatr Scand. 73:1986;337-347.
48. Shalev A., Hermesh H., Munitz H. The role of loading rate in neuroleptic malignant syndrome. Am J Psychiatry. 143:1986;1059.
49. Shalev A., Hermesh H., Munitz H. The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry. 145:1988;110-111.
50. Slack T., Stoudemire A. Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome. Gen Hosp Psychiatry. 11:1989;365-367.
51. Sullivan C.F. A possible variant of the neuroleptic malignant syndrome. Br J Psychiatry. 151:1987;689-690.
52. Surmont D.W.A., Colardyn F., De Reuck J. Fatal complication of neuroleptic drugs. Acta Neurol Belg. 84:1984;75-83.
53. Taylor M.A. Catatonia, a review of a behavioral neurologic syndrome. Neuropsychiatry Neuropsychobiol Behav Neurol. 3:1990;48-72.
54. Tollefson G. A case of neuroleptic malignant syndrome In vitro muscle comparison with malignant hypertermia . J Clin Psychopharmacol. 2:1982;266-270.
55. Van Putten T., Marder S.R. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 48:(suppl):1987;13.
56. Van Putten T., Beckson M., Marder S.R. The neuroleptic malignant syndrome manifested as a prolonged confusional state. J Clin Psychopharmacol. 8:1988;229-230.
57. Velamoor V.R., Fernando M.L.D., Williamson P. Incipient neuroleptic malignant syndrome? Br J Psychiatry. 156:1990;581-584.
58. Velamoor V.R., Norman R.M.G., Caroff S.N., Mann S.C., Sullivan K.A., Antelo R.E. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 182:1994;168-173.
59. White D.A. Catatonia and the NMS - A single entity? Br J Psychiatry. 161:1992;558-560.
60. White D.A., Robins A.H. Catatonia Harbinger of the neuroleptic malignant syndrome . Br J Psychiatry. 158:1991;419-421.